Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
Add more filters










Publication year range
1.
J Neuropathol Exp Neurol ; 79(4): 378-392, 2020 04 01.
Article in English | MEDLINE | ID: mdl-32016321

ABSTRACT

Although Gaucher disease can be accompanied by Lewy pathology (LP) and extrapyramidal symptoms, it is unknown if LP exists in Fabry disease (FD), another progressive multisystem lysosomal storage disorder. We aimed to elucidate the distribution patterns of FD-related inclusions and LP in the brain of a 58-year-old cognitively unimpaired male FD patient suffering from predominant hypokinesia. Immunohistochemistry (CD77, α-synuclein, collagen IV) and neuropathological staging were performed on 100-µm sections. Tissue from the enteric or peripheral nervous system was unavailable. As controls, a second cognitively unimpaired 50-year-old male FD patient without LP or motor symptoms and 3 age-matched individuals were examined. Inclusion body pathology was semiquantitatively evaluated. Although Lewy neurites/bodies were not present in the 50-year-old individual or in controls, severe neuronal loss in the substantia nigra pars compacta and LP corresponding to neuropathological stage 4 of Parkinson disease was seen in the 58-year-old FD patient. Major cerebrovascular lesions and/or additional pathologies were absent in this individual. We conclude that Lewy body disease with parkinsonism can occur within the context of FD. Further studies determining the frequencies of both inclusion pathologies in large autopsy-controlled FD cohorts could help clarify the implications of both lesions for disease pathogenesis, potential spreading mechanisms, and therapeutic interventions.


Subject(s)
Brain/pathology , Fabry Disease/pathology , Lewy Bodies/pathology , Lewy Body Disease/pathology , Neurons/pathology , Astrocytes/pathology , Brain/blood supply , Brain/metabolism , Fabry Disease/complications , Fabry Disease/metabolism , Humans , Lewy Bodies/metabolism , Lewy Body Disease/complications , Lewy Body Disease/metabolism , Male , Middle Aged , Neurons/metabolism , Trihexosylceramides/metabolism , alpha-Synuclein/metabolism
2.
Brain Pathol ; 26(3): 371-86, 2016 05.
Article in English | MEDLINE | ID: mdl-26193084

ABSTRACT

Alzheimer's disease (AD) represents the most frequent progressive neuropsychiatric disorder worldwide leading to dementia. We systematically investigated the presence and extent of the AD-related cytoskeletal pathology in serial thick tissue sections through all subcortical brain nuclei that send efferent projections to the transentorhinal and entorhinal regions in three individuals with Braak and Braak AD stage 0 cortical cytoskeletal pathology and fourteen individuals with Braak and Braak AD stage I cortical cytoskeletal pathology by means of immunostainings with the anti-tau antibody AT8. These investigations revealed consistent AT8 immunoreactive tau cytoskeletal pathology in a subset of these subcortical nuclei in the Braak and Braak AD stage 0 individuals and in all of these subcortical nuclei in the Braak and Braak AD stage I individuals. The widespread affection of the subcortical nuclei in Braak and Braak AD stage I shows that the extent of the early subcortical tau cytoskeletal pathology has been considerably underestimated previously. In addition, our novel findings support the concept that subcortical nuclei become already affected during an early 'pre-cortical' evolutional phase before the first AD-related cytoskeletal changes occur in the mediobasal temporal lobe (i.e. allocortical transentorhinal and entorhinal regions). The very early involved subcortical brain regions may represent the origin of the AD-related tau cytoskeletal pathology, from where the neuronal cytoskeletal pathology takes an ascending course toward the secondarily affected allocortex and spreads transneuronally along anatomical pathways in predictable sequences.


Subject(s)
Alzheimer Disease/pathology , Brain/pathology , tau Proteins , Aged , Cytoskeleton/pathology , Disease Progression , Female , Humans , Male , Middle Aged
3.
Brain Pathol ; 23(2): 165-77, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22925167

ABSTRACT

Huntington's disease (HD) is a polyglutamine disease and characterized neuropathologically by degeneration of the striatum and select layers of the neo- and allocortex. In the present study, we performed a systematic investigation of the cerebellum in eight clinically diagnosed and genetically confirmed HD patients. The cerebellum of all HD patients showed a considerable atrophy, as well as a consistent loss of Purkinje cells and nerve cells of the fastigial, globose, emboliform and dentate nuclei. This pathology was obvious already in HD brains assigned Vonsattel grade 2 striatal atrophy and did not correlate with the extent and distribution of striatal atrophy. Therefore, our findings suggest (i) that the cerebellum degenerates early during HD and independently from the striatal atrophy and (ii) that the onset of the pathological process of HD is multifocal. Degeneration of the cerebellum might contribute significantly to poorly understood symptoms occurring in HD such as impaired rapid alternating movements and fine motor skills, dysarthria, ataxia and postural instability, gait and stance imbalance, broad-based gait and stance, while the morphological alterations (ie ballooned neurons, torpedo-like axonal inclusions) observed in the majority of surviving nerve cells may represent a gateway to the unknown mechanisms of the pathological process of HD.


Subject(s)
Cerebellum/pathology , Huntington Disease/pathology , Purkinje Cells/pathology , Aged , Aged, 80 and over , Atrophy/pathology , Corpus Striatum/pathology , Disease Progression , Female , Humans , Male , Middle Aged
4.
J Neurotrauma ; 27(12): 2245-54, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20939694

ABSTRACT

Therapeutic hypothermia (TH) is still being explored as a therapeutic option after traumatic brain injury (TBI) but clinical data has not supported its efficacy. Experimental approaches were promising, but clinical data did not support its efficacy in the treatment of TBI. A novel approach of pharyngeal selective brain cooling (pSBC), recently introduced by our group, has been accompanied by superior neurofunctional, sensorimotor, and cognitive outcomes. This work is now extended by data on histomorphological and physical outcomes after pSBC in a model of experimental TBI. Male Sprague-Dawley rats were subjected to lateral fluid-percussion (LFP) brain injury, and randomized to the following experimental groups: (1) TBI with pSBC, (2) TBI without pSBC, and (3) sham animals. On day post-injury (DPI) 14, the animals were sacrificed and their brains were harvested for immunohistochemistry using the following antibodies: (1) glial fibrillary acidic protein (GFAP), (2) neurofilament (NF), and (3) synaptophysin (SY). In pSBC animals brain temperature was selectively lowered to 33 ± 0.5°C within 15 min post-injury, and maintained for 180 min after induction, while keeping rectal temperatures at physiological levels. Animals that had undergone pSBC showed a significantly faster recovery of body weight starting on DPI 3, and had gained substantially more weight than TBI-only animals on DPI 14 (p < 0.001), indicating superior physical recovery. Areas of cortical damage were significantly smaller in pSBC animals compared to TBI-only animals (p < 0.01). pSBC was associated with preservation of cortical tissue ipsilateral to the lesion, and superior physical recovery after experimental TBI. These results complement earlier reports in which pSBC was associated with superior neurofunctional and cognitive outcomes using the same experimental model.


Subject(s)
Brain Injuries/therapy , Cerebral Cortex/injuries , Hypothermia, Induced/methods , Analysis of Variance , Animals , Astrocytes/metabolism , Astrocytes/pathology , Brain Injuries/metabolism , Brain Injuries/pathology , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Glial Fibrillary Acidic Protein/metabolism , Immunohistochemistry , Male , Random Allocation , Rats , Rats, Sprague-Dawley
5.
Mol Biol Evol ; 26(6): 1379-89, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19282513

ABSTRACT

Changes in DNA methylation patterns during embryo development and differentiation processes are linked to the transcriptional plasticity of our genome. However, little is known about the evolutionary conservation of DNA methylation patterns and the evolutionary impact of epigenetic differences between closely related species. Here we compared the methylation patterns of CpG islands (CGIs) in the promoter regions of seven genes in humans and chimpanzees. We identified a block of CpGs in the cell cycle-related kinase (CCRK) gene that is more methylated in the adult human cortex than in the chimpanzee cortex and, in addition, it exhibits considerable intraspecific variation both in humans and chimpanzees. The species-specifically methylated region (SMR) lies between the almost completely methylated 5' region and the completely demethylated 3' region of the presumed CCRK CGI promoter. It is part of an Alu-Sg1 repeat that has been integrated into the promoter region in a common ancestor of humans and New World monkeys. This SMR is relatively hypomethylated in the rhesus monkey cortex and more or less completely methylated in the baboon cortex, indicating extraordinary methylation dynamics during primate evolution. The mRNA expression level of CCRK has also changed during the course of primate evolution. CCRK is expressed at much higher levels in human and baboon cortices, which display an average SMR methylation of 70% and 100%, respectively, than in chimpanzee and rhesus macaque cortices with an average SMR methylation of 35% and 40%, respectively. The observed evolutionary dynamics suggests a possibility that CCRK has been important for evolution of the primate brain.


Subject(s)
CpG Islands/genetics , Cyclin-Dependent Kinases/genetics , DNA Methylation/genetics , Frontal Lobe/metabolism , Promoter Regions, Genetic , Animals , Base Sequence , Cyclin-Dependent Kinases/metabolism , Female , Gene Expression , Humans , Macaca mulatta , Male , Molecular Sequence Data , Pan troglodytes , Papio , Cyclin-Dependent Kinase-Activating Kinase
6.
Hum Pathol ; 40(2): 270-8, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18755492

ABSTRACT

Pituitary carcinomas are exceedingly rare. At present, the sole diagnostic criterion is metastatic spread, either craniospinal or systemic. There is no agreement on a histologic, immunohistochemical, and/or ultrastructural definition. We report a clinically and morphologically well-documented example of pituitary thyrotropin cell carcinoma in a man with multiple endocrine neoplasia type 1 syndrome. The tumor produced thyrotropin, alpha-subunit, and prolactin and, through electron microscopy, was found to consist solely of Thyrotroph cells. Over a protracted course, craniospinal and systemic metastases were noted. The primary and metastatic deposits of this aggressive tumor were studied. To our knowledge, this tumor is the first reported case of thyrotropin cell carcinoma occurring in association with the multiple endocrine neoplasia type 1 syndrome. The literature regarding thyrotropin carcinomas is reviewed. Based on the study of several biopsies during disease progression, we believe that the carcinoma originated de novo without an intermediary adenoma phase.


Subject(s)
Carcinoma/secondary , Multiple Endocrine Neoplasia Type 1/pathology , Pituitary Neoplasms/pathology , Thyrotropin/biosynthesis , Adult , Carcinoma/metabolism , Central Nervous System Neoplasms/secondary , Humans , Immunohistochemistry , Magnetic Resonance Imaging , Male , Multiple Endocrine Neoplasia Type 1/metabolism , Pituitary Neoplasms/metabolism , Prolactin/biosynthesis
7.
Acta Neuropathol ; 113(4): 421-9, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17294202

ABSTRACT

Clinical signs frequently recognized in early phases of sporadic Parkinson's disease (PD) may include autonomic dysfunctions and the experience of pain. Early disease-related lesions that may account for these symptoms are presently unknown or incompletely known. In this study, immunocytochemistry for alpha-synuclein was used to investigate the first relay stations of the pain system as well as parasympathetic and sympathetic pre- and postganglionic nerve cells in the lower brainstem, spinal cord, and coeliac ganglion in 100 microm polyethylene glycol embedded sections from six autopsy individuals, whose brains were staged for PD-associated synucleinopathy. Immunoreactive inclusions were found for the first time in spinal cord lamina I neurons. Lower portions of the spinal cord downwards of the fourth thoracic segment appeared to be predominantly affected, whereas the spinal trigeminal nucleus was virtually intact. Additional involvement was seen in parasympathetic preganglionic projection neurons of the vagal nerve, in sympathetic preganglionic neurons of the spinal cord, and in postganglionic neurons of the coeliac ganglion. The known interconnectivities between all of these components offer a possible explanation for their particular vulnerability. Lamina I neurons (pain system) directly project upon sympathetic relay centers, and these, in turn, exert influence on the parasympathetic regulation of the enteric nervous system. This constellation indicates that physical contacts between vulnerable regions play a key role in the pathogenesis of PD.


Subject(s)
Ganglia, Parasympathetic/pathology , Ganglia, Sympathetic/pathology , Neurons/pathology , Parkinson Disease/pathology , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Neurons/metabolism , Parkinson Disease/complications , Peripheral Nervous System , Posterior Horn Cells/pathology , alpha-Synuclein/metabolism
8.
Mov Disord ; 21(12): 2042-51, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17078043

ABSTRACT

The synucleinopathy known as sporadic Parkinson's disease (PD) is a multisystem disorder that severely damages predisposed nerve cell types in circumscribed regions of the human nervous system. A recent staging procedure for the inclusion body pathology associated with PD proposes that, in the brain, the pathological process (formation of proteinaceous intraneuronal Lewy bodies and Lewy neurites) begins at two sites and continues in a topographically predictable sequence in six stages, during which components of the olfactory, autonomic, limbic, and somatomotor systems become progressively involved. In stages 1 to 2, the Lewy body pathology is confined to the medulla oblongata/pontine tegmentum and anterior olfactory structures. In stages 3 to 4, the substantia nigra and other nuclei of the basal mid- and forebrain become the focus of initially subtle and, then, severe changes. During this phase, the illness probably becomes clinically manifest. In the final stages 5 to 6, the lesions appear in the neocortex. This cross-sectional study originally was performed on 168 autopsy cases using material from 69 incidental cases and 41 clinically diagnosed PD patients as well as 58 age- and gender-matched controls. Here, the staging hypothesis is critically reconsidered and discussed.


Subject(s)
Inclusion Bodies/pathology , Parkinson Disease/pathology , Animals , Disease Progression , Humans , Parkinson Disease/physiopathology
9.
Brain Pathol ; 16(3): 218-27, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16911479

ABSTRACT

In the last years progress has been made regarding the involvement of the thalamus during the course of the currently known polyglutamine diseases. Although recent studies have shown that the thalamus consistently undergoes neurodegeneration in Huntington's disease (HD) and spinocerebellar ataxia type 2 (SCA2) it is still unclear whether it is also a consistent target of the pathological process of spinocerebellar ataxia type 3 (SCA3). Accordingly we studied the thalamic pathoanatomy and distribution pattern of ataxin-3 immunopositive neuronal intranuclear inclusions (NI) in nine clinically diagnosed and genetically confirmed SCA3 patients and carried out a detailed statistical analysis of our findings. During our pathoanatomical study we disclosed (i) a consistent degeneration of the ventral anterior, ventral lateral and reticular thalamic nuclei; (ii) a degeneration of the ventral posterior lateral nucleus and inferior and lateral subnuclei of the pulvinar in the majority of these SCA3 patients; and (iii) a degeneration of the ventral posterior medial and lateral posterior thalamic nuclei, the lateral geniculate body and some of the limbic thalamic nuclei in some of them. Upon immunocytochemical analysis we detected NI in all of the thalamic nuclei of all of our SCA3 patients. According to our statistical analysis (i) thalamic neurodegeneration and the occurrence of ataxin-3 immunopositive thalamic NI was not associated with the individual length of the CAG-repeats in the mutated SCA3 allele, the patients age at disease onset and the duration of SCA3 and (ii) thalamic neurodegeneration was not correlated with the occurrence of ataxin-3 immunopositive thalamic NI. This lack of correlation may suggest that ataxin-3 immunopositive NI are not immediately decisive for the fate of affected nerve cells but rather represent unspecific and pathognomonic morphological markers of SCA3.


Subject(s)
Intranuclear Inclusion Bodies/pathology , Machado-Joseph Disease/pathology , Nerve Degeneration/pathology , Nerve Tissue Proteins/metabolism , Neurons/pathology , Nuclear Proteins/metabolism , Repressor Proteins/metabolism , Thalamus/pathology , Adult , Age of Onset , Aged , Aged, 80 and over , Ataxin-3 , Female , Humans , Immunohistochemistry , Intranuclear Inclusion Bodies/metabolism , Machado-Joseph Disease/metabolism , Male , Middle Aged , Nerve Degeneration/metabolism , Nerve Tissue Proteins/genetics , Neurons/metabolism , Nuclear Proteins/genetics , Repressor Proteins/genetics , Thalamus/metabolism , Trinucleotide Repeats/genetics
10.
J Clin Microbiol ; 44(5): 1903-4, 2006 May.
Article in English | MEDLINE | ID: mdl-16672436

ABSTRACT

Early identification of Acanthamoeba in cerebrospinal fluid is mandatory to prevent fatal granulomatous amebic encephalitis. In the case presented here amebic trophozoites were detected in a routine cerebrospinal fluid sample. The antibiotic treatment and the apparently low virulence of this isolate were responsible for the benign progression of the infection.


Subject(s)
Acanthamoeba/isolation & purification , Amebiasis/diagnosis , Encephalitis/diagnosis , Acanthamoeba/genetics , Acanthamoeba/pathogenicity , Amebiasis/cerebrospinal fluid , Amebiasis/drug therapy , Amebiasis/parasitology , Amebicides/therapeutic use , Animals , Cerebrospinal Fluid/parasitology , DNA, Protozoan/genetics , DNA, Protozoan/isolation & purification , Encephalitis/cerebrospinal fluid , Encephalitis/drug therapy , Encephalitis/parasitology , Female , Humans , Middle Aged , Molecular Sequence Data , RNA, Protozoan/genetics , RNA, Ribosomal, 18S/genetics
11.
J Pharmacol Toxicol Methods ; 54(1): 62-70, 2006.
Article in English | MEDLINE | ID: mdl-16414289

ABSTRACT

INTRODUCTION: The development of novel antithrombotic agents directly affecting gene expression requires well established, reliable and useful in vitro model systems for initial validation of drug effects. Since most proteins involved in coagulation are synthesized by the liver, the hepatoblastoma cell line Hep G2 is introduced, here, as a model system to test nucleic acid based coagulation inhibitors. METHODS: Hep G2 cells were characterized with respect to prothrombin, tissue factor and factor VIII expression in dependence of cell culture conditions. Reliable enzyme linked immuno sorbent assays as well as viability tests were introduced that allow drug screening procedures with multiple probes in microplate format. Furthermore, a multiplex PCR-procedure has been presented that offers the possibility to simultaneously detect the effects of a selected compound on two coagulation proteins in comparison to a house keeping gene. RESULTS: Hep G2 cells were not affected in viability by cell culture conditions, while proliferation and the expression patterns of some coagulation factors were affected by the adhesion factor collagen. The prothrombin expression characteristics allowed us to choose a specific time point for the transfection of Hep G2 cells with prothrombin specific antisense oligonucleotides. Antisense oligonucleotides inhibited prothrombin expression independent from culture conditions and the effects were detected on protein-and mRNA-level. DISCUSSION: Nucleic acid based agents require cellular in vitro model systems since they affect the process of gene expression and not the gene product. Hep G2 cells are a useful model to study effects of novel nucleic acid based coagulation inhibitors with an antisense mechanism of action on protein and mRNA level.


Subject(s)
Blood Coagulation Factors/biosynthesis , Cell Culture Techniques/methods , Gene Expression Regulation/physiology , Gene Expression Regulation/drug effects , Humans , Oligonucleotides, Antisense/pharmacology , Tumor Cells, Cultured
12.
Neurosci Lett ; 396(1): 67-72, 2006 Mar 20.
Article in English | MEDLINE | ID: mdl-16330147

ABSTRACT

The progressive degenerative process associated with sporadic Parkinson's disease (sPD) is characterized by formation of alpha-synuclein-containing inclusion bodies in a few types of projection neurons in both the enteric and central nervous systems (ENS and CNS). In the brain, the process apparently begins in the brainstem (dorsal motor nucleus of the vagal nerve) and advances through susceptible regions of the basal mid-and forebrain until it reaches the cerebral cortex. Anatomically, all of the vulnerable brain regions are closely interconnected. Whether the pathological process begins in the brain or elsewhere in the nervous system, however, is still unknown. We therefore used immunocytochemisty to investigate the gastric myenteric and submucosal plexuses in 150 microm cryosections and 8 microm paraffin sections from five autopsy individuals, whose brains were also staged for Parkinson-associated synucleinopathy. alpha-synuclein immunoreactive inclusions were found in neurons of the submucosal Meissner plexus, whose axons project into the gastric mucosa and terminate in direct proximity to fundic glands. These elements could provide the first link in an uninterrupted series of susceptible neurons that extend from the enteric to the central nervous system. The existence of such an unbroken neuronal chain lends support to the hypothesis that a putative environmental pathogen capable of passing the gastric epithelial lining might induce alpha-synuclein misfolding and aggregation in specific cell types of the submucosal plexus and reach the brain via a consecutive series of projection neurons.


Subject(s)
Inclusion Bodies/pathology , Myenteric Plexus/physiopathology , Neurons/pathology , Parkinson Disease/physiopathology , Submucous Plexus/physiopathology , alpha-Synuclein/metabolism , Aged , Aged, 80 and over , Axonal Transport/physiology , Brain/metabolism , Brain/pathology , Brain/physiopathology , Disease Transmission, Infectious , Female , Gastric Mucosa/innervation , Gastric Mucosa/physiopathology , Humans , Inclusion Bodies/metabolism , Male , Middle Aged , Models, Neurological , Myenteric Plexus/metabolism , Myenteric Plexus/pathology , Nerve Net/metabolism , Nerve Net/pathology , Nerve Net/physiopathology , Neural Pathways/metabolism , Neural Pathways/pathology , Neural Pathways/physiopathology , Neurons/metabolism , Parkinson Disease/metabolism , Parkinson Disease/pathology , Prions/metabolism , Protein Folding , Submucous Plexus/metabolism , Submucous Plexus/pathology , Vagus Nerve/metabolism , Vagus Nerve/physiopathology
13.
Anesth Analg ; 101(2): 548-554, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16037174

ABSTRACT

UNLABELLED: Compared with bupivacaine, acute myotoxicity of ropivacaine is less severe. Thus, in this study we compared the long term myotoxic effects of both drugs in a clinically relevant setting. Femoral nerve catheters were inserted in anesthetized pigs, and either 20 mL of bupivacaine (5 mg/mL) or ropivacaine (7.5 mg/mL) was injected. Subsequently, bupivacaine (2.5 mg/mL) and ropivacaine (3.75 mg/mL) were continuously infused (8 mL/h) over 6 h. Control animals were treated with corresponding volumes of normal saline. After 7 and 28 days, respectively, muscle samples were dissected at the former injection sites, and histological patterns of muscle damage were blindly scored (0 = no damage to 3 = marked lesions/myonecrosis) and compared. No morphological tissue changes were detected in control animals. In the observed period, both local anesthetics induced morphologically identical patterns of calcific myonecrosis, formation of scar tissue, and a marked rate of fiber regeneration. However, bupivacaine's effects were constantly more pronounced than those of ropivacaine. These data show that both drugs induce irreversible skeletal muscle damage in a clinically relevant model, and confirm the exceeding rate of myotoxicity of bupivacaine. However, the clinical impact of these long term myotoxic effects still has to be assessed. IMPLICATIONS: In a period of 4 wk after peripheral nerve block, both long-acting local anesthetics, bupivacaine and ropivacaine, produced calcific myonecrosis suggestive of irreversible skeletal muscle damage. In comparison with ropivacaine, however, the extent of bupivacaine-induced muscle lesions was significantly larger.


Subject(s)
Amides/toxicity , Anesthetics, Local/toxicity , Bupivacaine/toxicity , Muscular Diseases/chemically induced , Nerve Block , Peripheral Nerves , Animals , Muscle Cells/drug effects , Muscle Cells/pathology , Muscle Fibers, Skeletal/pathology , Muscle, Skeletal/pathology , Muscular Diseases/pathology , Necrosis , Ropivacaine , Swine
14.
Brain Dev ; 26(5): 307-15, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15165671

ABSTRACT

Whereas several studies have addressed the activation of microglia (the resident mononuclear phagocytes of the brain) and macrophages within the nervous system in experimental animal models of congenital and induced hydrocephalus, little is known of their state of activation or regional distribution in human fetal hydrocephalus. This investigation aimed to address such questions. Ten human fetal cases [20-36 gestational weeks (GW) at postmortem] previously diagnosed with hydrocephalus on ultrasound examination in utero, and 10 non-hydrocephalic controls (22-38 GW at postmortem) were assessed immufcnohistochemically with antibodies directed against MHC class II and CD68 antigens, and lectin histochemistry with Lycopersicon esculentum (tomato lectin). Adjacent sections were also immunoreacted with an antiserum to laminin to detect cerebral blood vessels. Eight out of the 10 hydrocephalus cases showed numerous CD68 and tomato lectin-positive macrophages located at focal regions along the ependymal lining of the lateral ventricles (particularly within the occipital horn). However, only five of these cases demonstrated MHC class II positive macrophages associated with the ventricular lining. Microglial reactivity within periventricular regions could also be identified using the lectin in four cases, two of which were also immunoreactive with CD68 (but not with MHC class II). By comparison, in control cases five out of 10 fetal brains (aged between 20 and 24 GW) showed few or no ependymal or supraependymal macrophages. One case at 28 GW, and cases at 32 and 38 GW (two of which were diagnosed with intrauterine hypoxic-ischemia) did, however, show some MHC class II (CD68 negative) cells located at the ependymal surface. Nevertheless, these were not as numerous or intensely immunoreactive as in the hydrocephalus cases. Microglia interspersed throughout the intermediate zone and circumscribing the basal ganglia were within normal confines in all cases examined. Hydrocephalic cases additionally showed focal regions of hypovascularization or alterations in the structure and orientation of capillaries within periventricular areas, compared to controls. The macrophage response detected at the ependymal lining of the ventricles and within the periventricular area in hydrocephalus may be related both to the severity of hydrocephalus and the age of the fetus.


Subject(s)
Brain/pathology , Fetal Diseases/pathology , Hydrocephalus/pathology , Macrophages/pathology , Microglia/pathology , Adult , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Cause of Death , Cerebrovascular Circulation/physiology , Female , Fetal Diseases/physiopathology , Genes, MHC Class II/genetics , Gestational Age , Humans , Hydrocephalus/physiopathology , Immunohistochemistry , Laminin/metabolism , Male , Plant Lectins , Pregnancy
15.
Brain Pathol ; 14(1): 109-10, 115, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14997943

ABSTRACT

The July 2003 Case of the Month (COM). A 62-year-old female patient experienced progressive muscular weakness over the last ten years, involving shoulder and pelvic girdle muscles, paraspinal and facial muscles. A biopsy was taken from the left deltoid muscle where hepatitis vaccination had taken place 4 weeks previously. The specimen revealed macrophagic myofasciitis due to the injection of aluminium-bound vaccines. The finding can be reproduced experimentally by injecting vaccines in rats. The pathomechanism is supposed to involve immune stimulation due to long term persistence of the adjuvant. Macrophagic myofasciitis has been suggested to occasionally cause myopathy but is supposed to be unrelated to the underlying myopathy in our patient.


Subject(s)
Aluminum Hydroxide/adverse effects , Macrophages/pathology , Muscle Weakness/etiology , Muscle Weakness/pathology , Muscle, Skeletal/pathology , Viral Hepatitis Vaccines/adverse effects , Diagnosis, Differential , Female , Humans , Inclusion Bodies/chemistry , Inclusion Bodies/ultrastructure , Macrophages/ultrastructure , Mass Spectrometry , Microscopy, Electron , Middle Aged , Muscle Weakness/physiopathology , Muscle, Skeletal/ultrastructure , Muscular Dystrophy, Facioscapulohumeral/pathology
16.
Acta Neuropathol ; 107(2): 176-80, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14634758

ABSTRACT

We report here on the first documented case of profound alterations specifically affecting the microglial population within the nervous system during the fetal period. This case, derived at gestational week 12, was one amongst a series of second trimester brains currently being investigated with respect to microglial colonization of the human fetal brain. No significant pathological alterations could be identified upon gross macroscopy or following microscopic analysis of serial brain sections stained with cresyl fast violet (Nissl). By contrast, sections stained immunohistochemically to detect MHC class II (CR3/43) and CD68 (PG-M1) antigens revealed a marked pathological change in the morphology and density of microglia within the CNS. Specifically, labeled cells within the rostral telencephalon were clearly hypertrophied and emitted numerous, branched processes in all directions, appearing in an atypical 'hyper-ramified' state uncharacteristic of microglia found in normal brains at this age. However, cells located elsewhere in the CNS (for example in the thalamus and internal capsule) appeared in a less differentiated state (small, rounded cells lacking processes) when compared to those within normal age-matched control brains. The total density and distribution of these labeled cells far outnumbered that seen in normal development. As far as we are aware, such an anomaly specifically affecting microglia, has not been documented previously. Consequently, this case represents the first of its kind, and the remarkable observations outlined in this study bear considerable significance from a neuropathological standpoint for future investigations into pathological changes affecting microglia in the central nervous system during the fetal period.


Subject(s)
Central Nervous System/pathology , Fetus/abnormalities , Gestational Age , Microglia/pathology , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Central Nervous System/abnormalities , Central Nervous System/metabolism , Embryonic and Fetal Development , Female , Humans , Immunohistochemistry/methods , Major Histocompatibility Complex/physiology , Microglia/metabolism , Pregnancy , Staining and Labeling/methods
17.
Anesth Analg ; 97(4): 1173-1179, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14500177

ABSTRACT

UNLABELLED: Bupivacaine causes muscle damage. However, the myotoxic potency of ropivacaine is still unexplored. Therefore, we performed this study to compare the effects of bupivacaine and ropivacaine on skeletal muscle tissue in equipotent concentrations. Femoral nerve catheters were inserted into anesthetized minipigs, and 20 mL of either bupivacaine (5 mg/mL) or ropivacaine (7.5 mg/mL) was injected. Subsequently, bupivacaine (2.5 mg/mL) and ropivacaine (3.75 mg/mL) were continuously infused over 6 h. Control animals were treated with corresponding volumes of normal saline. Finally, muscle samples were dissected at injection sites. After processing and staining, histological patterns of muscle damage were blindly examined, scored (0 = no damage to 3 = myonecrosis), and statistically analyzed. After normal saline, only interstitial edema was found. Bupivacaine treatment caused severe tissue damage (score, 2.3 +/- 0.7), whereas ropivacaine induced fiber injury of a significantly smaller extent (score, 1.3 +/- 0.8). Furthermore, bupivacaine, but not ropivacaine, induced apoptosis in muscle fibers. In summary, both drugs induce muscle damage with similar histological patterns. Compared with bupivacaine, which induces both necrosis and apoptosis, the tissue damage caused by ropivacaine is significantly less severe. We conclude that ropivacaine's myotoxic potential is more moderate in comparison with that of bupivacaine. IMPLICATIONS: After continuous peripheral nerve blockades, the long-acting local anesthetics bupivacaine and ropivacaine both induce fiber necrosis in porcine skeletal muscle tissue. In comparison with ropivacaine, bupivacaine causes tissue damage of a significantly larger extent and additionally induces apoptosis in skeletal muscle cells.


Subject(s)
Amides/adverse effects , Anesthetics, Local/adverse effects , Bupivacaine/adverse effects , Muscular Diseases/chemically induced , Nerve Block , Peripheral Nerves , Animals , Edema/pathology , Female , In Situ Nick-End Labeling , Microscopy, Electron , Muscle Fibers, Skeletal/pathology , Muscle Fibers, Skeletal/ultrastructure , Muscle, Skeletal/pathology , Muscle, Skeletal/ultrastructure , Muscular Diseases/pathology , Ropivacaine , Swine , Swine, Miniature , Tissue Fixation
19.
Ann N Y Acad Sci ; 985: 22-33, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12724145

ABSTRACT

Data on the fetal development of the human amygdala is reviewed with special reference to major ontogenetic events. In the fifth gestational month, the inferior portion of the amygdala reveals cell-dense columns merging with the ganglionic eminence (proliferative zone) in Nissl-stained sections. These columns contain vimentin-positive fibers and can therefore be regarded as migrational routes. In the sixth and seventh months, distinct reorganization of the cytoarchitectonics takes place. The sequential occurrence of afferens can be visualized using anti-GAP-43; moreover, outgrowing axons appear to reach the periphery of the ganglionic eminence. The latter may thus represent an intermediate target for growing axons using anti-calbindin and anti-calretinin. Migrating and immature amygdaloid neurons can be shown in the fifth month. From the eighth month onwards, various nonpyramidal neurons and pyramidal neurons are immunolabeled. Transient expression of calretinin in pyramidal neurons is observed. When punctate calbindin and calretinin immunostaining in the fifth and eighth months is compared, distinct redistribution is observed. On the whole, it is apparent that the amygdala has reached a high degree of maturity in the eighth month. At this developmental stage, AKAP79, being enriched in postsynaptic densities, shows a characteristic nuclear-specific distribution pattern. The latter largely corresponds to the expression pattern of NMDAR1. Thus, AKAP79 may have a preference for anchoring enzymes to glutamate receptors. The aforementioned results provide a basis for investigations on subtle changes in pathologically altered material, such as hemorrhage, in the ganglionic eminence of preterm infants.


Subject(s)
Amygdala/embryology , Embryonic and Fetal Development , Amygdala/anatomy & histology , Amygdala/cytology , Biomarkers/analysis , Gestational Age , Humans , Nerve Tissue Proteins/analysis
20.
J Neuropathol Exp Neurol ; 61(5): 413-26, 2002 May.
Article in English | MEDLINE | ID: mdl-12030260

ABSTRACT

The substantia nigra is not the induction site in the brain of the neurodegenerative process underlying Parkinson disease (PD). Instead, the results of this semi-quantitative study of 30 autopsy cases with incidental Lewy body pathology indicate that PD in the brain commences with the formation of the very first immunoreactive Lewy neurites and Lewy bodies in non-catecholaminergic neurons of the dorsal glossopharyngeus-vagus complex, in projection neurons of the intermediate reticular zone, and in specific nerve cell types of the gain setting system (coeruleus-subcoeruleus complex, caudal raphe nuclei, gigantocellular reticular nucleus), olfactory bulb, olfactory tract, and/or anterior olfactory nucleus in the absence of nigral involvement. The topographical parcellation of the nuclear grays described here is based upon known architectonic analyses of the human brainstem and takes into consideration the pigmentation properties of a few highly susceptible nerve cell types involved in PD. In this sample and in all 58 age- and gender-matched controls, Lewy bodies and Lewy neurites do not occur in any of the known prosencephalic predilection sites (i.e. hippocampal formation, temporal mesocortex, proneocortical cingulate areas, amygdala, basal nucleus of Meynert, interstitial nucleus of the diagonal band of Broca, hypothalamic tuberomamillary nucleus).


Subject(s)
Glossopharyngeal Nerve/pathology , Locus Coeruleus/pathology , Olfactory Bulb/pathology , Parkinson Disease/pathology , Vagus Nerve/pathology , Aged , Aged, 80 and over , Female , Humans , Lewy Bodies/chemistry , Lewy Bodies/pathology , Male , Nerve Tissue Proteins/analysis , Olfactory Pathways/pathology , Raphe Nuclei/pathology , Reticular Formation/pathology , Substantia Nigra/pathology , Synucleins
SELECTION OF CITATIONS
SEARCH DETAIL
...